Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes

Blood

Volumn 90, Issue 5, 1997, Pages 2027-2036

  Syrovets, Tatjana ^b   Thillet, Joëlle ^b   Chapman, M John ^b   Simmet, Thomas ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; CHEMOATTRACTANT; CYCLIC GMP; LIPOPROTEIN A;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MIGRATION; CHEMOTAXIS; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0030882882     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.2027     Document Type: Article

References (61)

1. Utermann G: The mysteries of lipoprotein(a). Science 246:904, 1989
2. Scanu AM, Scandiani L: Lipoprotein(a): Structure, biology, and clinical relevance. Adv Intern Med 36:249, 1991
3. Howard GC, Pizzo SV: Biology of disease. Lipoprotein(a) and its role in atherothrombotic disease. Lab Invest 69:373, 1993
4. Dahlén GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 108:111, 1994
5. Gonzales-Gronow M, Edelberg JM, Pizzo SV: Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry 28:2374, 1989
6. Hajjar KA, Gavish D, Breslow JL, Nachman RT: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303, 1989
7. Harpel PC, Gordon BR, Parker TS: Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 86:3847, 1989
8. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF: A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339:301, 1989
9. Ezratty A, Simon DI, Loscalzo J: Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 32:4628, 1993
10. Harpel PC, Herman A, Zhang X, Ostfeld I, Borth W: Lipoprotein(a), plasmin modulation, and atherogenesis. Thromb Haemost 74:382, 1995
11. Miles LA, Fless G, Scanu A, Baynham P, Sebald MT, Skocir P, Curtiss LK, Levin EG, Hoover-Plow JL, Plow EF: Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 73: 458, 1995
12. Durrington PN: Lipoprotein (a). Baillière's Clin Endocrinol Metabol 9:773, 1995
13. Weide I, Römisch J, Simmet T: Contact activation triggers stimulation of the monocyte 5-lipoxygenase pathway via plasmin. Blood 83:1941, 1994
14. Weide I, Tippler B, Syrovets T, Simmet T: Plasmin is a specific stimulus of the 5-lipoxygenase pathway of human peripheral monocytes. Thromb Haemost 76:561, 1996
15. Syrovets T, Tippler B, Rieks M, Simmet T: Plasmin is a potent and specific chemoattractant for human peripheral monocytes acting via a cyclic guanosine monophosphate-dependent pathway. Blood 89:4574, 1997
16. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher, DeBakey ME, Lawrie GM, Morrisett JD: Quantitation and localization of apolipoproteins (a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 9:593, 1989
17. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U: Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579, 1989
18. Jamieson DG, Usher DC, Rader DJ, Lavi E: Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 147:1567, 1995
19. Ala27. Gene 184:263, 1997
20. Kola A, Baensch M, Bautsch W, Hennecke M, Klos A, Casaretto M, Köhl J: Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis. Immunotechnology 2:115, 1996
21. 4057 of lipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 90:11643, 1993
22. Weide I, Simmet T: Leukotriene formation by peripheral monocytes in contact-activated human blood. Thromb Res 71:185, 1993
23. Wilkinson PC: Micropore filter methods for leukocyte chemotaxis. Methods Enzymol 162:38, 1988
24. Kramer IM, van der Bend RL, Tool ATJ, van Blitterswijk WJ, Roos D, Verhoeven AJ: 1-O-Hexadecyl-2-O-methylglycerol, a novel inhibitor of protein kinase C, inhibits the respiratory burst in human neutrophils. J Biol Chem 264:5876, 1989
25. Weller PF, Reyom SW, Picard ST, Ackerman SJ, Dvorak AM: Cytoplasmic lipid bodies of neutrophils: Formation induced by cis-unsaturated fatty acids and mediated by protein kinase C. J Cell Biol 113:137, 1991
26. Hebert JM, Augereau JM, Gleye J, Maffrand JP: Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172:993, 1990
27. Mülsch A, Busse R, Liebau S, Förstermann U: LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther 247: 283, 1988
28. Francis SH, Noblett BD, Todd BW, Wells JN, Corbin JD: Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol Pharmacol 34:506, 1988
29. 2+ mobilization, and cellular responses to chemoattractants in human monocytes. J Immunol 137:271, 1986
30. Sozzani S, Luini W, Molino M, Jilek P, Bottazzi B, Cerletti C, Matsushima K, Mantovani A: The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J Immunol 147:2215, 1991
31. Friberger P, Knös M, Gustavsson S, Aurell L, Claeson G: Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 7:138, 1978
32. Collen D, Lijnen HR, De Cock F, Durieux JP, Loffet A: Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases. Biochem Biophys Acta 165:158, 1980
33. Lu H, Soria C, Li H, Soria J, Lijnen HR, Perrot JY, Caen JP: Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation. Thromb Haemost 65:67, 1991
34. Huby T, Schröder W, Doucet C, Chapman J, Thillet J: Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): Relevance to fibrin binding. Biochemistry 34:7385, 1995
35. Lowry VH, Rosebrough NJ, Fair AL: Protein measurement with the folin phenol reagent. J Biol Chem 193:265, 1951
36. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M: Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1α and MIP-1β on human monocytes. Eur J Immunol 25:64, 1995
37. Chuluyan HE, Schall TJ, Yoshimura T, Issekutz AC: II-1 activation of endothelium supports VLA-4 (CD49d/CD29)-mediated monocyte transendothelial migration to C5a, MIP-1α, RANTES, and PAF but it inhibits migration to MCP-1: A regulatory role for endothelium-derived MCP-1. J Leukoc Biol 58:71, 1995
38. Marder SR, Chenoweth DE, Goldstein IM, Perez HD: Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol 134:3325, 1985
39. Gallin JI, Sandler JA, Clyman RI, Manganiello VC, Vaughan M: Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. J Immunol 120:492, 1978
40. Stephens CG, Snyderman R: Cyclic nucleotides regulate the morphologic alterations required for chemotaxis in monocytes. J Immunol 128:1192, 1982
41. Perretti M, Ahluwalia A, Harris JG, Goulding NJ, Flower RJ: Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J Immunol 151:4306, 1993
42. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228, 1994
43. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801, 1993
44. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 84:2995, 1987
45. Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85:2805, 1988
46. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner GM: Interaction of lipoprotein(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis 8:851, 1988
47. Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C: Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 8:4035, 1989
48. Kreuzer J, Lloyd MB, Bok D, Fless G, Scanu AM, Lusis AJ, Haberland ME: Lipoprotein (a) displays increased accumulation compared with low density lipoprotein in the murine arterial wall. Chemistry and Physics of Lipids 67/68:175, 1994
49. Smith EB, Cochran S: Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis 84:173, 1990
50. Felez J, Miles LA, Plescia J, Plow EF: Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J Cell Biol 111:1673, 1990
51. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM: Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 87:767, 1991
52. Snyder ML, Polacek D, Scanu AM, Fless GM: Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. J Biol Chem 267:339, 1992
53. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J 9:939, 1995
54. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF: Role of cell-surface lysines in plasminogen binding to cells: Identification of α-enolase as a candidate plasminogen receptor. Biochemistry 30:1682, 1991
55. Hajjar KA, Jacovina AT, Chacko J: An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 269:21191, 1994
56. Jürgens G, Marth E, Kostner GM, Holasek A: Investigation of the Lp(a)lipoprotein: Lipoprotein aggregating and enzymatic activity associated with the Lp(a)polypeptide. Artery 3:13, 1977
57. Chulkova TM: Enzymatic properties of active form of human apolipoprotein(a). Biochem Biophys Res Commun 171:555, 1990
58. Gabel BR, Koschinsky ML: Analysis of the proteolytic activity of a recombinam form of apolipoprotein(a). Biochemistry 34:15777, 1995
59. Snyderman R, Uhing RJ: Chemoattractant stimulus-response coupling, in Gallin JI, Goldstein IM, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates (ed 2). New York, NY, Raven Press, 1992, p 421
60. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL: Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 266:2459, 1991
61. Nachman RL: Thrombosis and atherogenesis: Molecular connections. Blood 79:1897, 1992